Allied Health & Imaging · Independent exam preparation
Medical Dosimetry Certification Exam (CMD) Study Guide
Practise target coverage, dose calculations, image registration and plan safety with 60 focused concepts, worked decisions and original CMD learning drills.
By CertMedbry · Updated 30 October 2026
Practise deciding whether targets are covered, dose calculations are credible, registrations are usable and treatment plans can be delivered safely. This guide connects radiation physics with planning decisions through calculations, image interpretation and clinical reasoning. Its 60 concepts are selective: the official MDCB Test Specifications Matrix defines the full examination scope. Use the questions to expose reasoning gaps and the flashcards to strengthen recall.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which administration and blueprint does this guide follow?
It follows the Applicant Handbook 2027 for the January 21–23, 2027 administration, posted September 4, 2026. The handbook explicitly uses the matrix derived from the 2023 Job Task Analysis. It gives no separate matrix implementation date. A September 2027 administration is also announced; its administration-specific handbook should be checked separately.
MDCB Applicant Handbook 2027 · MDCB Announce Dates for the 2027 Exam
How many questions are there, and how many are scored?
The handbook specifies 155 questions. A small percentage are randomly embedded, unscored items used to evaluate new questions. It does not give an exact scored-question or unscored-question count.
How long is the examination?
The allowed completion time is 3 hours 50 minutes, equivalent to 230 minutes. The handbook provides no scheduled break and instructs candidates to arrive 30 minutes before their appointment.
How is the examination delivered?
The examination is delivered in English at computer-based testing centers through Meazure Learning. The handbook lists centers in the United States and Canada and other international locations. It does not describe an adaptive testing algorithm. The examination is designed around knowledge for U.S.-based dosimetry practice.
Which item styles should candidates prepare for?
The handbook presents four-option multiple-choice and drag-and-drop examples and explicitly includes performance-based multiple-choice and contouring items. Performance-based work uses MDCB's ProKnow DS platform for plan evaluation, DVHs, isodose interpretation, anatomy, beam arrangements and contouring. The 20 questions here are independent single-best-answer drills and do not reproduce that interface or the contouring assessment.
What are the official domain weights?
The percentages of scored questions are Radiation Physics 14%; Localization 8%; Treatment Planning 42%; Dose Calculation Methods 13%; Brachytherapy 5%; Radiation Protection 9%; and Quality Assurance & Standard of Care 9%. The 60 concepts approximate these weights. Each 20-item question or flashcard set contains eight Treatment Planning items, three Radiation Physics items, two each in Localization, Dose Calculation Methods, Radiation Protection and Quality Assurance & Standard of Care, and one Brachytherapy item.
Which eligibility pathway is this guide written for?
The guide takes the first-time Route 1 candidate as its reference pathway. The session handbook requires a bachelor's degree and graduation from a U.S. JRCERT-accredited dosimetry program lasting at least 12 months, with specified academic and clinical-completion documentation. Route 2 provisions concern qualifying historical reapplicants and do not identify a separate examination. The eligibility section retains a '2026 Exam' heading inside the 2027 handbook; individual eligibility questions belong with MDCB.
Can performance on these exercises predict an examination result?
No. These exercises diagnose selected knowledge and reasoning gaps; they do not provide a validated pass prediction. MDCB also states that successful completion of its practice tests does not predict successful performance on the CMD examination. Use the official handbook for examination scoring policies and the complete test matrix.
How should candidates prepare for performance-based work?
Use the authorized MDCB tutorials to practise multiplanar navigation, window and level adjustment, absolute dose displays, cumulative and differential DVHs, contour editing and final submission. The handbook states that images are head-first supine unless otherwise indicated. For this administration, it asks candidates to establish ProKnow access by January 7 and states that tutorial access closes 72 hours before the first examination day.
This independent guide supports preparation for the MDCB Medical Dosimetry Certification Exam awarding the Certified Medical Dosimetrist credential. Medical Dosimetry Certification Exam, MDCB Certification Exam and CMD exam identify the same examination in MDCB materials. These are original educational exercises, not official examination items. Numerical exercises state their own assumptions. Identified protocol examples apply within their stated contexts; neither exercises nor protocol examples establish patient-specific prescriptions or universal clinical limits.
Outline used: Applicant Handbook 2027, January 21–23, 2027 administration; posted September 4, 2026; CMD Test Specifications Matrix derived from the 2023 Job Task Analysis. The assigned workbook label maps to the MDCB examination awarding the Certified Medical Dosimetrist credential.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Radiation Physics14%
1.How does half-life determine remaining source activity?
Radioactive decay reduces the number of unstable nuclei exponentially: A(t) = A0 × 2^(−t/T½). Each elapsed half-life leaves half the preceding activity, regardless of the starting amount. The decay constant is ln(2)/T½; mean lifetime is its reciprocal and is longer than the half-life. Identify the reference date and use matching time units before calculating. Activity measures transformations per second, rather than energy absorbed by tissue.
Apply it
A training source has an activity of 12 GBq on its reference date. After three stated half-lives, its activity is 12 × (1/2)^3 = 1.5 GBq. The elapsed number of half-lives controls the fraction remaining.
Common pitfall: Subtracting the same activity each half-life treats decay as linear. Confusing half-life with mean lifetime also produces a systematic error in exponential calculations.
Radiation Oncology Physics: A Handbook for Teachers and Students
2.How are treatment photons and electrons produced?
A medical linear accelerator accelerates electrons using electromagnetic fields. In photon mode, electrons strike a target and produce bremsstrahlung with a continuous energy spectrum. In electron mode, the electron beam is transported and shaped for treatment without using that photon-production target in the same way. Characteristic X-rays arise from atomic shell transitions and have discrete energies. Distinguish the accelerated particle from the radiation ultimately selected for patient treatment.
Apply it
A machine accelerates electrons but directs them onto a high atomic number target before treatment. Identify the delivered therapeutic beam as bremsstrahlung photons, rather than assuming that the accelerator's initial electron beam reaches the patient directly.
Common pitfall: The word accelerator does not uniquely identify the treatment modality. Likewise, a nominal photon energy does not mean every photon has that energy.
Radiation Oncology Physics: A Handbook for Teachers and Students
3.Which photon interactions explain attenuation and energy transfer?
Photoelectric absorption removes a photon and transfers energy to an electron; its probability depends strongly on photon energy and material composition. Compton scattering transfers part of the photon energy to an electron while the scattered photon continues. Pair production requires photon energy above 1.022 MeV and creates an electron–positron pair. Interaction dominance depends on energy and absorber, so diagnostic image contrast and megavoltage treatment behavior cannot be interpreted using one universal interaction rule.
Apply it
When comparing diagnostic CT with a megavoltage photon beam, explain why material composition can produce strong diagnostic contrast while electron density is especially important for Compton interactions in typical soft-tissue treatment calculations. The energy range changes the interpretation.
Common pitfall: Pair production's threshold is a necessary condition, not proof that it dominates. Avoid assigning one interaction to every photon energy or tissue composition.
Radiation Oncology Physics: A Handbook for Teachers and Students
4.How does half-value layer describe attenuation?
For a monoenergetic photon beam in narrow-beam geometry, intensity follows I = I0e^(−μx), and the half-value layer is ln(2)/μ. Each half-value layer halves the unscattered intensity under those assumptions. A polyenergetic beam can harden as lower-energy photons are preferentially removed, so successive half-value layers need not be identical. Broad-beam measurements also include scattered radiation. Specify spectrum and geometry before extending an attenuation calculation to shielding.
Apply it
A narrow monoenergetic beam crosses a thickness equal to four stated half-value layers. Its unscattered intensity becomes 1/16 of the initial value. Before applying this result to a room barrier, assess scattering and spectral assumptions.
Common pitfall: A narrow-beam transmission calculation does not automatically predict broad-beam dose beyond a barrier. Scatter buildup and beam hardening can invalidate simple repeated-halving assumptions.
Radiation Oncology Physics: A Handbook for Teachers and Students · IAEA Safety Reports Series 47: Radiation Protection in the Design of Radiotherapy Facilities
5.When is the inverse-square law appropriate?
For an effectively pointlike source without intervening attenuation or scatter changes, fluence and dose rate vary inversely with the square of distance. Thus D2/D1 = (r1/r2)^2 when the other relevant conditions remain unchanged. Use distances from the radiation source, rather than from an arbitrary equipment surface. Extended sources, near-source geometry, patient scatter and changing field dimensions can require additional treatment-specific factors beyond this geometric relationship alone.
Apply it
A point-source training measurement is 8 units per hour at 1 meter. At 2 meters, with the same medium and negligible scatter changes, the predicted rate is 2 units per hour. Doubling distance quarters the rate.
Common pitfall: Using distance from the patient surface instead of the source gives the wrong ratio. Extended-source behavior may also depart from a point-source approximation.
Radiation Oncology Physics: A Handbook for Teachers and Students · CDC: ALARA Recommendations
6.What distinguishes absorbed dose, activity and equivalent dose?
Absorbed dose is energy imparted per unit mass; one gray equals one joule per kilogram. Activity counts nuclear transformations and is expressed in becquerels, or transformations per second. Equivalent dose applies radiation weighting for protection purposes and is expressed in sieverts. Exposure describes ionization produced by photons in air and is a different quantity again. Match the quantity to the question before converting units; equal numerical values do not make these measures interchangeable.
Apply it
A 0.02 kg sample absorbs 0.06 J. Its absorbed dose is 0.06/0.02 = 3 Gy. Neither the source's activity nor an occupational monitoring quantity can replace this energy-per-mass calculation without additional information about irradiation conditions.
Common pitfall: Becquerels cannot be converted directly to grays using a universal constant. Source emissions, geometry, attenuation and absorption determine how activity produces absorbed dose.
NIST: Water Calorimetry Primary Standards for Absorbed Dose to Water · Radiation Oncology Physics: A Handbook for Teachers and Students
7.What does a Hounsfield unit actually measure?
A Hounsfield unit expresses a reconstructed CT attenuation coefficient relative to water: HU = 1000(μtissue − μwater)/μwater. Water is therefore near zero and air near −1000 under the conventional scale. HU is an imaging quantity influenced by acquisition and reconstruction conditions, rather than a universal direct measurement of electron density. Treatment planning converts CT values through a commissioned calibration appropriate to the scanner, protocol and calculation method.
Apply it
Two scans of an insert produce different CT values after a protocol change. Before accepting their dosimetric equivalence, compare acquisition settings, artifacts and the validated CT-to-density relationship. Similar-looking images do not establish identical quantitative calibration for calculation.
Common pitfall: Interpreting HU as electron density without calibration overlooks scanner and protocol dependence. A sharp-looking reconstruction can still contain unsuitable quantitative information for dose calculation.
Radiation Oncology Physics: A Handbook for Teachers and Students · AAPM Report 85: Tissue Inhomogeneity Corrections for Megavoltage Photon Beams
8.How do photon, electron and proton depth-dose patterns differ?
Megavoltage photons exhibit buildup followed by a depth-dose decrease, with dose continuing beyond the target. Electrons have a comparatively limited useful penetration and a rapid distal falloff, making them useful for selected superficial targets. Protons deposit energy with a pronounced end-of-range peak that can be combined to cover target depth. Their finite range makes path length and stopping-power uncertainty particularly important. Select a modality using target depth, geometry and uncertainty, not penetration alone.
Apply it
A superficial target lies immediately above a deeper sensitive structure. Compare an electron plan's useful range and distal falloff with photon dose beyond the target, while checking surface coverage, lateral scatter and irregular tissue geometry before choosing the treatment approach.
Common pitfall: Finite range does not guarantee perfect normal-tissue sparing. Electron scatter and proton range uncertainty can place clinically meaningful dose outside the intended target region.
Radiation Oncology Physics: A Handbook for Teachers and Students · NCI: External Beam Radiation Therapy for Cancer
Localization8%
9.Why must simulation positioning be reproducible?
The planning image represents the geometry used to calculate treatment, so positioning must be achievable repeatedly with the actual treatment equipment. Immobilization reduces variability but does not eliminate internal organ motion or setup error. Evaluate comfort, indexing, arm position, available clearance and whether the scan includes all relevant anatomy and beam paths. A position that looks favorable on one scan is unsuitable if pain or equipment limitations prevent reliable daily reproduction.
Apply it
A patient maintains an arms-up position briefly but develops pain before the expected treatment duration. Reconsider support and positioning before completing simulation, then confirm that the revised position accommodates imaging, beam clearance and reproducible immobilization throughout treatment.
Common pitfall: Increasing immobilization rigidity cannot compensate for an intolerable position. Missing external anatomy or treatment-device information may also undermine an otherwise reproducible simulation dataset.
NCI: External Beam Radiation Therapy for Cancer · Radiation Oncology Physics: A Handbook for Teachers and Students
10.How should respiratory motion be characterized at simulation?
Respiratory-resolved imaging samples anatomy across breathing states to estimate motion that a single static CT may miss. Irregular breathing, sorting artifacts and limited sampling can distort that estimate. Review the underlying phases and target trajectory rather than trusting a composite image alone. Motion management may use an internal target approach, breath hold, gating or tracking, with technique selection tied to observed motion, patient reproducibility and the capabilities of the delivery system.
Apply it
A moving lesion appears discontinuous in one respiratory phase, and the recorded breathing trace is irregular. Inspect neighboring phases and source images before defining its motion envelope. Consider whether repeat acquisition or a more reproducible motion-management approach is needed.
Common pitfall: A maximum-intensity projection is not a universal substitute for phase review. Adjacent dense anatomy and respiratory sorting artifacts can obscure or exaggerate target motion.
Radiation Oncology Physics: A Handbook for Teachers and Students · AAPM TG-290: Respiratory Motion Management for Particle Therapy
11.What separates rigid from deformable image registration?
Rigid registration applies translations and rotations while preserving shape and internal distances. Deformable registration permits spatially varying displacement to represent anatomical changes. Neither method proves that corresponding tissues have been correctly matched. Choose the transformation for the clinical task, then assess its result in the relevant anatomy. A good rigid bone match may be inadequate for a changing organ, while an apparently smooth deformation may still be anatomically wrong.
Apply it
A planning CT and MRI show consistent skull geometry but different neck flexion. A single rigid transform may align the skull while leaving lower neck anatomy mismatched. Evaluate whether separate regions or a validated deformable approach serve the intended task.
Common pitfall: Deformable registration is not automatically superior because it has more degrees of freedom. Greater flexibility can conceal implausible tissue correspondence behind convincing image overlap.
12.How should an image registration be verified locally?
Registration quality must be assessed for its intended use and anatomical region. Inspect landmarks, organ boundaries and correspondence in axial, sagittal and coronal views, especially near the target and critical structures. A global similarity score can conceal a clinically important local mismatch. For deformable registration, evaluate plausibility of displacement and tissue behavior as well as overlap. The required accuracy depends on whether the result supports localization, contour propagation or dose mapping.
Apply it
A fused MRI appears well aligned overall, but a small target beside an organ at risk is displaced locally. Inspect nearby landmarks in all planes and correct the registration or its use before transferring contours into the planning dataset.
Common pitfall: A high overlap score for a large organ can coexist with an important boundary error. Verification must examine the anatomy that drives the clinical decision.
13.Which anatomy should guide an image-based setup correction?
Image guidance should localize the anatomy or validated surrogate relevant to the treatment target. Bone, fiducials, soft tissue and external surfaces measure different aspects of position and may not move together. Distinguish a persistent systematic offset from variable daily motion, and apply corrections within the established imaging and action protocol. A setup correction can improve target alignment while changing the relationship to nearby organs, so review the relevant anatomy after matching.
Apply it
Pelvic bones align with the planning image, but target-associated fiducials show a consistent displacement. Investigate target position using the approved matching method and assess surrounding anatomy. A bone match alone cannot establish that the internal target is correctly localized.
Common pitfall: An external surface or bony landmark is a surrogate, not direct proof of internal target position. Daily imaging does not eliminate all intrafraction motion.
AAPM TG-132: Image Registration and Fusion in Radiotherapy · Radiation Oncology Physics: A Handbook for Teachers and Students
Treatment Planning42%
14.What distinguishes GTV, CTV, ITV and PTV?
The gross tumor volume represents demonstrable tumor. The clinical target volume includes tissue requiring treatment for known or suspected microscopic disease. An internal target volume incorporates relevant internal motion, while the planning target volume is a geometric construct accounting for uncertainties in positioning and motion according to the adopted framework. These volumes serve different purposes. Microscopic spread is a clinical target-definition issue; geometric uncertainty is not evidence that additional tissue contains tumor.
Apply it
A visible lung lesion moves during breathing and also requires consideration of microscopic extension. Define the disease-bearing target first, represent internal motion using the chosen method, and then account for residual geometric uncertainty without confusing those separate reasons for expansion.
Common pitfall: Using one arbitrary expansion for microscopic disease and setup uncertainty hides distinct assumptions. An ITV also does not automatically account for every remaining setup error.
15.Why create a planning organ-at-risk volume?
A planning organ-at-risk volume incorporates geometric uncertainty around an organ at risk so planning can account for possible displacement relative to the dose distribution. It is particularly useful when a steep gradient lies near a sensitive structure. The PRV supplements rather than replaces the anatomical organ contour. Evaluate the actual organ's dose and any protocol-defined PRV criteria separately, because the two structures answer different questions about anatomy and uncertainty.
Apply it
A narrow high-dose region lies beside the spinal cord. Evaluate the cord contour and an appropriately defined PRV when assessing gradient placement. If the PRV overlaps the target, document the competing objectives rather than silently removing the overlap.
Common pitfall: A PRV is not additional normal tissue known to have the organ's biology. Applying an organ constraint to its PRV without checking the protocol can misstate compliance.
16.How is the esophagus identified and contoured on thoracic CT?
The esophagus is a collapsible muscular tube descending behind the trachea and in front of the vertebral column before passing through the diaphragm to the stomach. These relationships help distinguish it from the airway. Follow its soft-tissue wall continuously on CT using mediastinal window settings; a collapsed lumen does not mean the organ has ended. The RTOG thoracic atlas defines its extent from the cricoid level through the gastroesophageal junction to the stomach and includes the wall through the muscular layers to the fatty adventitia. See the [NCI SEER anatomy reference](https://training.seer.cancer.gov/anatomy/digestive/regions/pharynx.html) and [RTOG thoracic contouring atlas](https://pmc.ncbi.nlm.nih.gov/articles/PMC3933280/).
Apply it
Identify the tube immediately posterior to the upper thoracic trachea, then follow it inferiorly in axial and orthogonal views to the gastroesophageal junction. If a contour encloses only the visible lumen, expand it to the anatomical outer wall before evaluating esophageal dose.
Common pitfall: Contouring only the lumen omits irradiated esophageal wall. Ending the contour where the lumen becomes indistinct also truncates the organ; use anatomical continuity and the defined superior and inferior landmarks.
MDCB Applicant Handbook 2027 · AAPM TG-132: Image Registration and Fusion in Radiotherapy
17.How does cervical cancer extent determine the roles of pelvic EBRT and brachytherapy?
Cervical cancer can extend into the parametrium, vagina and adjacent pelvic organs and spread to pelvic or para-aortic nodes. Parametrial invasion without pelvic-wall extension defines FIGO IIB; pelvic nodal disease defines IIIC1 and para-aortic nodal disease IIIC2. Definitive treatment for locally advanced disease commonly combines pelvic external-beam radiation, concurrent cisplatin-based chemotherapy and brachytherapy. EBRT treats the broader pelvic disease distribution, while brachytherapy concentrates dose around the cervical primary. Para-aortic involvement changes the nodal region requiring treatment assessment. Bladder and rectal mucosal invasion indicate adjacent-organ extension, rather than merely proximity. See [NCI Cervical Cancer Treatment PDQ](https://www.cancer.gov/types/cervical/hp/cervical-treatment-pdq).
Apply it
A case has cervical tumor extending into the parametrium and documented pelvic nodal involvement. Include both primary extension and involved nodal disease in target review; a cervix-only target omits known disease. Assess the EBRT and brachytherapy contributions together, including nearby bladder and rectum exposure.
Common pitfall: A satisfactory central brachytherapy distribution does not establish treatment of pelvic nodal disease. Curative intent also does not supply target boundaries: anatomical extension and nodal findings determine what must be addressed.
NCI: External Beam Radiation Therapy for Cancer · Radiation Oncology Physics: A Handbook for Teachers and Students
18.How are D95 and V20 read from a cumulative DVH?
A cumulative dose-volume histogram reports the volume receiving at least each dose. D95 is the dose received by at least 95% of the specified structure; V20 is the volume receiving at least 20 dose units, commonly Gy when explicitly stated. Confirm whether volume is relative or absolute and whether dose is absolute or percentage. These metrics summarize coverage or exposure but do not show where the underdosed or irradiated tissue is located.
Apply it
A target has D95 = 48 Gy and a lung has V20 = 24%. Interpret these as 95% of the target receiving at least 48 Gy and 24% of that lung volume receiving at least 20 Gy.
Common pitfall: V20 does not mean 20% of the prescription dose unless explicitly defined that way. D95 also does not describe the dose to every target voxel.
Radiation Oncology Physics: A Handbook for Teachers and Students
19.Why must isodose review accompany DVH review?
A DVH discards spatial location: different dose distributions can produce similar histogram summaries. Isodose review shows whether a cold region lies within clinically important disease, whether a hotspot occupies target or normal tissue, and whether a gradient crosses an organ boundary. Examine multiple planes and relevant dose levels rather than one favorable slice. The decisive question is how dose relates to anatomy, not simply whether summary statistics fall within selected limits.
Apply it
Two plans have the same target D95, but one places its coldest region along a clinically important target interface. Compare spatial coverage and nearby organ doses before selecting a plan. The matching histogram value does not establish clinical equivalence.
Common pitfall: An acceptable DVH cannot prove that a hotspot is safely located. Conversely, one attractive isodose slice cannot establish three-dimensional target coverage or organ protection.
Radiation Oncology Physics: A Handbook for Teachers and Students
20.How do serial and parallel organ behavior affect dose interpretation?
A serial-organ model emphasizes the consequences of injuring a critical functional segment, making high local dose especially important. A parallel-organ model emphasizes the amount of functioning tissue preserved, so volume effects and mean dose can be informative. These are useful approximations rather than absolute labels. Biologically related models, including equivalent uniform dose, compress nonuniform distributions using tissue-specific assumptions. Evaluate the relevant organ endpoint and model parameters before using a single summary metric.
Apply it
One plan reduces mean organ dose but increases a small high-dose region near a structure with a critical serial function. Compare the endpoint-specific high-dose metric as well as the mean. A lower average alone may not represent lower complication risk.
Common pitfall: Calling an organ parallel does not make every hotspot harmless. Equivalent uniform dose also depends on model assumptions and cannot replace anatomical and protocol-based review.
AAPM Report 166: The Use and QA of Biologically Related Models for Treatment Planning
21.What does an actual protocol specify beyond an organ-dose number?
The [UW16037 protocol, NCT02843568, version June 9, 2022](https://cdn.clinicaltrials.gov/large-docs/68/NCT02843568/Prot_SAP_000.pdf), provides a concrete example. Its conventional-fractionation cohort receives 60–66 Gy in 1.8–2.0 Gy fractions. Section 5.5.3 defines the lung evaluation volume as both lungs minus the CTV and specifies V20 no greater than 37%; it alternatively describes an optimal mean lung dose of no more than 20 Gy. The spinal cord's total direct-plus-scatter dose must not exceed 50.5 Gy and has highest priority. The esophageal mean below 34 Gy is strongly recommended rather than absolute. Thus structure definition, fractionation, metric and requirement strength all matter.
Apply it
For a 60 Gy in 30 fractions teaching case using this protocol's V20 criterion, a bilateral-lungs-minus-CTV V20 of 35% meets that criterion; 39% does not. A value calculated on lungs minus GTV answers a different structural definition. A passing lung metric does not establish that the cord requirement or all other criteria pass.
Common pitfall: Do not silently replace CTV subtraction with GTV subtraction, turn a recommended mean into a mandatory limit, or carry conventional-fractionation values into SBRT. This is a named protocol example, not a universal tolerance table.
MDCB Applicant Handbook 2027 · AAPM Report 166: The Use and QA of Biologically Related Models for Treatment Planning
22.How is biologically effective dose calculated?
For equal fractions under the basic linear-quadratic model with complete repair, BED = nd[1 + d/(α/β)], where n is fraction count and d is dose per fraction. The α/β ratio is tissue- and endpoint-dependent. Larger fractions increase the quadratic contribution, especially for lower α/β values. State the selected ratio and assumptions before comparing schedules; the basic expression does not automatically account for repopulation, incomplete repair or every high-dose treatment setting.
Apply it
For a hypothetical course of five 6 Gy fractions and α/β = 10 Gy, BED = 30 × (1 + 6/10) = 48 Gy10. Repeat with another endpoint's α/β rather than treating this value as universal.
Common pitfall: Equal physical total doses do not imply equal BED. Using the tumor's α/β for a late normal-tissue endpoint can reverse the apparent safety comparison.
AAPM Report 166: The Use and QA of Biologically Related Models for Treatment Planning
23.How does EQD2 support comparison of treatment courses?
EQD2 expresses a schedule's modeled biological effect as an equivalent total dose delivered in 2 Gy fractions: EQD2 = BED/[1 + 2/(α/β)]. Use the same tissue endpoint and α/β when comparing or combining courses. In reirradiation, biological conversion is only one part of assessment; spatial overlap, prior dose uncertainty, elapsed time and tissue recovery assumptions also matter. A converted scalar total does not establish the dose to corresponding anatomy.
Apply it
A hypothetical course has BED = 60 Gy3. Its EQD2 is 60/(1 + 2/3) = 36 Gy. Before adding a previous course, establish anatomical correspondence and use consistent endpoint assumptions rather than summing prescription values alone.
Common pitfall: Adding tumor EQD2 to normal-tissue EQD2 mixes different biological assumptions. A long interval also does not justify assuming complete recovery without an explicit basis.
AAPM Report 166: The Use and QA of Biologically Related Models for Treatment Planning · AAPM TG-132: Image Registration and Fusion in Radiotherapy
24.Why do repair and overall treatment time matter?
Fractionation allows repair of sublethal radiation injury between exposures, with the extent of repair depending on tissue and time. Closely spaced fractions may violate a complete-repair assumption. Overall treatment time can also influence biological effect through processes such as tumor repopulation. Therefore, two courses with the same total dose and fraction size are not necessarily biologically equivalent if their timing differs. Select a model whose repair and time assumptions match the comparison.
Apply it
A proposed schedule places two fractions much closer together than the schedule used for a simple BED comparison. Recognize that the calculation assumes complete repair and examine whether an incomplete-repair model is needed before interpreting biological equivalence between schedules.
Common pitfall: The basic BED formula contains no explicit treatment-time term. Its numerical agreement cannot prove that interruptions, acceleration or closely spaced fractions have no biological consequence.
AAPM Report 166: The Use and QA of Biologically Related Models for Treatment Planning
25.How do LET and RBE differ?
Linear energy transfer describes energy deposited per unit track length, while relative biological effectiveness compares doses of reference and test radiation producing the same biological endpoint. RBE depends on radiation quality, dose, tissue and endpoint; it is not simply another unit for LET. Particle-beam planning requires attention to how physical and biologically weighted doses are defined. A reported dose value must be interpreted with the adopted biological model and its limitations.
Apply it
Two particle-beam regions have different radiation quality despite similar physical dose. Explain why their biological effects need not be identical, and verify whether the displayed dose is physical or biologically weighted before comparing target coverage and organ exposure.
Common pitfall: Higher LET does not provide a universal numerical RBE conversion. Treating biologically weighted dose as ordinary physical dose conceals assumptions needed for meaningful comparison.
Radiation Oncology Physics: A Handbook for Teachers and Students · IAEA-TECDOC-1560: Dose Reporting in Ion Beam Therapy
26.How do forward and inverse planning make different decisions?
Forward planning begins with selected beam arrangements and modifiers, then iteratively adjusts them after dose calculation. Inverse planning begins with specified objectives and uses optimization to determine fluence or delivery parameters. Both depend on accurate contours, appropriate beam geometry and clinical judgment. An optimizer cannot infer an omitted organ or an incorrectly stated priority. Choose the method for the clinical geometry and delivery system, then evaluate the resulting dose and practical deliverability.
Apply it
A simple target has a localized hotspot that can be reduced with a small field-in-field adjustment. A more complex concave target may benefit from inverse optimization. In either case, verify the final calculated distribution and relevant organ doses.
Common pitfall: Inverse planning does not turn objectives into guaranteed clinical constraints. Forward planning also remains an active design process rather than merely accepting the first calculated beam arrangement.
Radiation Oncology Physics: A Handbook for Teachers and Students · AAPM Report 166: The Use and QA of Biologically Related Models for Treatment Planning
27.How should optimization objectives be interpreted?
Optimization objectives mathematically penalize selected dose features, such as target underdose or organ overdose. Weights control tradeoffs within the objective function; they do not directly express a probability of clinical success. An objective may be missed when goals conflict or delivery is limited. Assess the final recalculated dose, including structures and endpoints omitted from optimization. Changing one weight can redistribute dose elsewhere, so review the entire plan after each meaningful optimization change.
Apply it
Increasing an organ-sparing weight improves its DVH but reduces target coverage at an overlapping boundary. Inspect the spatial conflict and compare the prescribed clinical priorities. Further weight increases alone cannot resolve an inherently incompatible pair of dose goals.
Common pitfall: A low optimization cost is not a certificate of clinical acceptability. Unmodeled structures and differences between optimization dose and final dose may remain consequential.
AAPM Report 166: The Use and QA of Biologically Related Models for Treatment Planning
28.When should automated contours and plans be accepted?
Automation reproduces a defined process or learned pattern; it does not independently establish anatomical truth or prescription suitability. Review generated structures for local boundaries, missing regions and unusual anatomy, then inspect the resulting dose against the actual prescription and organ definitions. Templates can propagate consistent errors when their assumptions do not fit the case. Validate automated workflows for their intended use and preserve human review of the clinically meaningful inputs and outputs.
Apply it
An automated workflow produces a satisfactory target DVH, but its organ contour omits superior slices. Correct and approve the contour, recompute the organ metrics and reoptimize if necessary. The favorable initial statistic was based on an incomplete structure.
Common pitfall: Consistency is not accuracy: automation can repeat the same error reliably. A plausible plan summary cannot compensate for an incorrect contour or prescription input.
AAPM TG-275: Effective Physics Plan and Chart Review · AAPM TG-132: Image Registration and Fusion in Radiotherapy
29.How should conformity and dose falloff be judged in stereotactic planning?
Conformity describes how closely a selected high-dose volume matches the target, while dose falloff describes how dose decreases outside it. Neither metric guarantees coverage or organ protection. Definitions of conformity and gradient indices vary, so state the formula and prescription isodose used. Stereotactic plans place high doses near steep gradients, making contour, localization and calculation errors particularly consequential. Evaluate target coverage, intermediate-dose spread and adjacent critical structures together.
Apply it
A small-target plan has a favorable conformity index but places a steep gradient across a nearby critical structure. Inspect the relevant small-volume organ dose and geometric uncertainty. A single conformity value cannot establish that the plan tolerates realistic setup variation.
Common pitfall: A smaller prescription isodose volume can improve one index while underdosing the target. Comparing indices calculated with different definitions can also misrank plans.
Radiation Oncology Physics: A Handbook for Teachers and Students · IAEA-TECDOC-1560: Dose Reporting in Ion Beam Therapy
30.How do nodal extent and central anatomy change lung cancer planning?
A medically inoperable, node-negative stage I NSCLC and an unresectable stage III tumor involving mediastinal nodes require different treatment approaches. SBRT is widely used for the former; definitive chemoradiation is a major approach for suitable patients with unresectable stage III disease. Known nodal disease must be represented in target selection rather than planning only around the pulmonary mass. Central tumors place major airways and esophagus near the high-dose region, so a peripheral-tumor SBRT schedule cannot be transferred automatically. Beam arrangements must balance target coverage with exposure of lung, heart, esophagus and cord. See [NCI NSCLC Treatment PDQ](https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq).
Apply it
Compare a peripheral node-negative lesion with a lung primary accompanied by documented mediastinal nodal involvement. For the latter, review primary and involved nodal targets and the intervening critical anatomy. A small field around the primary alone misses known regional disease.
Common pitfall: Small primary-tumor size does not establish early-stage disease when nodes are involved. More beam directions may improve conformity while increasing low-dose lung exposure; evaluate that tradeoff using the relevant organ metrics.
Radiation Oncology Physics: A Handbook for Teachers and Students · NCI: External Beam Radiation Therapy for Cancer
31.What delivery tradeoffs distinguish IMRT and VMAT?
IMRT shapes intensity through modulated beam fluence, while VMAT delivers modulation during gantry rotation with coordinated machine parameters. Either technique can produce conformal distributions, but plan quality and efficiency depend on geometry, modulation and machine capabilities. Greater modulation can increase sensitivity to delivery limitations and make verification more demanding. Compare clinically relevant dose metrics with treatment time, mechanical feasibility and verification results instead of assuming one technique is superior for every patient.
Apply it
Two plans meet the same target and organ objectives, but one requires substantially more complex modulation. Compare delivery feasibility and verification evidence alongside any time benefit. Select using the actual plans rather than treating the technique name as a quality ranking.
Common pitfall: A shorter delivery is not proof of better dosimetry, and a more complex fluence pattern is not proof of better treatment. Evaluate measurable clinical and delivery consequences.
NCI: External Beam Radiation Therapy for Cancer · AAPM TG-218: IMRT Measurement-Based Verification QA
32.How should electron energy and bolus be selected?
Electron energy affects useful penetration and distal dose falloff, while bolus changes the effective surface and moves the depth-dose pattern toward shallower tissue. Choose energy using the target's full depth and the commissioned beam data, then evaluate underlying organ dose. Bolus may improve superficial coverage but also alters scatter and geometry. Irregular surfaces, oblique incidence and air gaps can disrupt a simple water-phantom expectation, so the actual setup must be represented.
Apply it
An electron plan covers the distal target but leaves insufficient surface dose. Evaluate a suitable bolus arrangement and recalculate coverage and deeper dose. Confirm reproducible contact and account for contour irregularity rather than increasing energy solely to address the surface deficit.
Common pitfall: Higher electron energy may improve depth coverage while increasing unnecessary deep dose. Bolus is not merely a surface-dose adjustment; it changes the effective treatment depth.
Radiation Oncology Physics: A Handbook for Teachers and Students · AAPM TG-71: Monitor Unit Calculations for External Photon and Electron Beams
33.How does breast cancer nodal spread change postoperative target selection?
Breast cancer regional spread can involve ipsilateral axillary, infraclavicular, supraclavicular and internal mammary nodes. After mastectomy, four or more positive axillary nodes identify a high-risk setting in which chest-wall and regional nodal irradiation has traditionally been used. These targets address potential locoregional residual disease even when no gross breast mass remains. The axilla is lateral to the breast, while internal mammary nodes occupy the parasternal region; a chest-wall-only arrangement cannot be assumed to cover all prescribed nodal regions. Beam selection must explicitly cover the selected volumes and assess heart and lung exposure. See [NCI Breast Cancer Treatment PDQ](https://www.cancer.gov/types/breast/hp/breast-treatment-pdq).
Apply it
A postmastectomy case has four involved axillary nodes and a prescription for chest wall plus regional nodes. Review coverage of each designated nodal region as well as the chest wall. Compare conformal or modulated arrangements according to the actual anatomy and organ-dose tradeoffs.
Common pitfall: The absence of a visible postoperative tumor does not remove microscopic-disease targets. Incidental dose from chest-wall fields is not proof of adequate nodal coverage, and the selected nodal levels should not be inferred from a generic field name.
TRACO: Introduction to Radiation Oncology, October 15, 2024 · Radiation Oncology Physics: A Handbook for Teachers and Students
34.How do total-body and total-skin techniques differ?
Total-body irradiation seeks dose throughout the body using a technique designed for large anatomical extent and controlled organ exposure. Total-skin electron irradiation instead emphasizes the skin and superficial tissues while limiting deeper penetration. Their geometry, penetration requirements and dose-uniformity challenges differ substantially. Extended distances, patient positioning, shielding and surface irregularity may require special measurements and calculations. Identify the intended treated depth before selecting a technique or transferring assumptions from another large-field procedure.
Apply it
A planning discussion concerns widespread superficial skin disease rather than irradiation of deep body tissues. Recognize why a total-skin electron approach addresses a different depth objective from total-body irradiation, then examine the specialized coverage and dosimetry requirements of the proposed technique.
Common pitfall: A large treated surface does not make total-skin treatment equivalent to total-body treatment. Deep-dose objectives and technique-specific uniformity measurements cannot be transferred without justification.
Radiation Oncology Physics: A Handbook for Teachers and Students
35.Why does proton planning require robustness evaluation?
Proton dose depends strongly on the water-equivalent path to the target, so setup changes and stopping-power uncertainty can move dose distributions and distal falloff. Nominal coverage alone may therefore overstate reliability. Robust evaluation calculates clinically relevant uncertainty scenarios and checks target and organ behavior across them. Robust optimization incorporates selected uncertainty scenarios during planning, but its protection is limited to modeled assumptions. Evaluate anatomical changes separately when they fall outside those scenarios.
Apply it
A proton plan meets nominal target coverage, but a stated range-uncertainty scenario creates distal undercoverage. Compare scenario-based target and organ results and revise beam geometry or optimization. Increasing nominal coverage alone may not address the underlying path-length sensitivity.
Common pitfall: A geometric PTV expansion does not automatically resolve range uncertainty. A robust plan also cannot be presumed reliable for every unmodeled anatomical change or motion pattern.
AAPM TG-290: Respiratory Motion Management for Particle Therapy · IAEA-TECDOC-1560: Dose Reporting in Ion Beam Therapy
36.How does respiratory motion create scanning-beam interplay?
In scanned particle delivery, individual spots or layers are delivered at particular times while the target and surrounding tissues may move. The interaction between temporal delivery and anatomical motion can create dose heterogeneity beyond that predicted by a static calculation. Repeated fractions or repainting may reduce some effects but do not guarantee elimination. Assess motion, delivery timing and mitigation together using an appropriate evaluation method rather than treating motion as only a geometric expansion problem.
Apply it
A scanned-beam plan covers a moving target on every static phase calculation, yet delivery timing could repeatedly align spots with particular breathing states. Evaluate temporal interplay and whether gating, breath hold or repainting provides an appropriate and reproducible mitigation strategy.
Common pitfall: Static phase robustness and temporal interplay are related but different assessments. Good coverage on separate respiratory images cannot prove the delivered time-dependent dose is adequately uniform.
AAPM TG-290: Respiratory Motion Management for Particle Therapy
37.When should anatomical change trigger adaptive assessment?
Adaptive assessment is warranted when observed anatomical or positional changes may make the original calculated dose unrepresentative. Examples include altered external contour, organ filling, target size or beam-path composition. Determine whether the change affects target coverage, organ exposure or dose-calculation assumptions, using appropriate imaging and calculation. Adaptation requires review of the new contours, prescription relationship, dose and delivery data; a visually different image alone does not establish the magnitude of dosimetric change.
Apply it
Repeated treatment images show weight loss and a changed external contour along several beam paths. Assess whether the original plan still represents current anatomy and whether a new calculation or replanning is needed, rather than adjusting setup solely to improve image overlap.
Common pitfall: A setup shift cannot correct every anatomical deformation. Conversely, every visible change does not require replanning; the decision should follow its demonstrated dosimetric and clinical consequences.
AAPM TG-275: Effective Physics Plan and Chart Review · AAPM Report 85: Tissue Inhomogeneity Corrections for Megavoltage Photon Beams
38.How does TG-203 classify cardiac-device risk during radiotherapy?
TG-203 combines pacing dependence, cumulative dose to the cardiac implantable electronic device and neutron production. Without neutrons, pacing-independent patients are low risk below 2 Gy, medium risk at 2–5 Gy and high risk above 5 Gy; pacing-dependent patients are medium risk through 5 Gy and high risk above it. Neutron-producing treatment is high risk regardless of these dose bands. Secondary neutrons can cause stochastic single-event upsets, including resets, even outside the useful beam. Photons above 10 MV and proton therapy are treated as neutron producing. The categories guide management, not guaranteed malfunction thresholds; manufacturer guidance and individual circumstances qualify their use. See [TG-203, Table VI and Section 7](https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mp.13838).
Apply it
Record device dependence, estimate cumulative device dose and identify neutron production before selecting monitoring intensity and emergency arrangements with cardiology and physics. Pacing dependence increases the consequences of interruption; low estimated device dose cannot downgrade neutron-producing treatment.
Common pitfall: The report treats 10 MV photons as non-neutron-producing for this risk framework despite small physical neutron yields. Neither an out-of-field location nor a dose below 2 Gy guarantees normal device operation.
AAPM TG-203: Management of Radiotherapy Patients with Implanted Cardiac Devices
Dose Calculation Methods13%
39.How do dose-per-MU factors determine monitor units?
A monitor-unit calculation relates prescribed dose to the calibrated dose per MU under the actual treatment conditions. Field-size output, depth, distance, off-axis position and beam modifiers may all change that relationship. Multiply factors using a consistent reference convention, then divide the required dose by the resulting dose per MU. Identify what each factor already includes to avoid double counting. An independent calculation should test the clinical setup rather than merely reproduce TPS inputs.
Apply it
A hypothetical setup has calibrated output 1 cGy/MU and a combined applicable factor of 0.80. Delivering 160 cGy at the specified point requires 160/(1 × 0.80) = 200 MU, provided the stated reference and geometry are consistent.
Common pitfall: A transmission factor below one generally increases MU for a fixed point dose. Applying the same correction twice can produce a plausible-looking but incorrect result.
AAPM TG-71: Monitor Unit Calculations for External Photon and Electron Beams
40.When should PDD and TMR be used differently?
Percentage depth dose compares dose at depth with dose at a reference depth in a fixed source-to-surface geometry. Tissue-maximum ratio compares doses while maintaining the relevant source-to-point geometry and defined field conditions. Their distance and scatter conventions differ, so they cannot be interchanged without conversion. Select data consistent with SSD or isocentric calculation geometry and the stated field-size definition. Apply inverse-square corrections only where the chosen formalism requires them.
Apply it
A calculation changes from a fixed-SSD setup to an isocentric point-at-depth setup. Rebuild the calculation using the appropriate commissioned depth-dose quantity and geometry, checking field-size definitions and distance factors rather than simply replacing one table value with another.
Common pitfall: Adding an inverse-square factor already embedded in the selected depth-dose relationship double counts geometry. PDD and TMR values require their reference conditions to remain meaningful.
AAPM TG-71: Monitor Unit Calculations for External Photon and Electron Beams
41.How do wedges, MLCs and bolus alter calculated dose?
Beam modifiers change more than the visible field outline. Wedges alter fluence across the field and may affect spectrum and scatter; MLCs introduce transmission, leaf-end effects and modulation geometry; bolus changes the effective tissue surface and depth. Calculation and verification must represent the actual modifier and delivery method. A single attenuation factor may approximate one reference condition but cannot describe every spatial effect across a modulated or irregular treatment field.
Apply it
An independent calculation agrees on an open field but diverges after a wedge is introduced. Check wedge identity, orientation, field-size dependence and the factor convention before altering the prescription. The new discrepancy points toward modifier modeling or setup representation.
Common pitfall: Treating every modifier as uniform attenuation misses spatial dose changes. Bolus also cannot be modeled correctly by reducing MU while leaving the patient geometry unchanged.
AAPM TG-71: Monitor Unit Calculations for External Photon and Electron Beams · AAPM Report 85: Tissue Inhomogeneity Corrections for Megavoltage Photon Beams
42.Why do tissue interfaces challenge dose algorithms?
Dose depends on energy transport by secondary charged particles as well as photon attenuation. At low-density regions, small fields and tissue interfaces, charged-particle equilibrium may be reduced and lateral transport becomes important. A correction based only on radiological path length cannot fully represent these effects. Select an algorithm commissioned for the relevant geometry and inspect situations near its known limitations. Heterogeneity correction is a transport problem, not merely a change in effective depth.
Apply it
A small photon field treats a target surrounded by low-density lung. Compare whether the selected algorithm represents lateral electron transport and interface effects. A simple attenuation correction may predict target dose inaccurately despite using the correct average path density.
Common pitfall: Matching water-phantom data does not prove accuracy in lung or at interfaces. More accurate input density cannot rescue an algorithm that omits the relevant transport physics.
AAPM Report 85: Tissue Inhomogeneity Corrections for Megavoltage Photon Beams · AAPM TG-105: Clinical Implementation of Monte Carlo Treatment Planning
43.When is a density override justified?
A density override replaces image-derived material information with a selected value or material assignment. It can address known artifacts or represent a defined planning assumption, but it must have a defensible physical basis. Review the affected beam paths, chosen material, region extent and calculation model. Overrides may conceal real uncertainty if used merely to improve a dose result. Document the rationale and evaluate sensitivity when the true composition or anatomy remains uncertain.
Apply it
Metal artifacts produce implausible CT values in adjacent tissue. Assess the artifact and available imaging, then apply only justified material assignments with physics review. Compare dose sensitivity to reasonable assumptions rather than assigning water to every unusual region in the scan.
Common pitfall: An override changes the calculation model, not the patient's anatomy. Replacing a real cavity or implant with convenient density can create falsely reassuring coverage or organ-dose estimates.
AAPM Report 85: Tissue Inhomogeneity Corrections for Megavoltage Photon Beams
44.How should Monte Carlo uncertainty be interpreted?
Monte Carlo methods estimate radiation transport using sampled particle histories. Finite sampling produces statistical uncertainty, which generally decreases approximately with the inverse square root of the number of independent histories. More histories reduce random noise but do not correct an inaccurate source model, wrong anatomy or inappropriate material assignment. Interpret the reported uncertainty definition and location, since low-dose regions may have large relative uncertainty even when absolute fluctuations are small.
Apply it
A calculation's statistical uncertainty is 2% under a stated convention. Reducing it to about 1% requires roughly four times as many independent histories. After increasing sampling, still verify beam modeling and density inputs because their errors do not average away.
Common pitfall: A smoother Monte Carlo dose distribution is not proof of greater overall accuracy. Statistical precision addresses sampling variation, while systematic modeling and input errors require separate validation.
AAPM TG-105: Clinical Implementation of Monte Carlo Treatment Planning
45.Why does dose-grid resolution matter near small structures?
A dose grid samples a continuous dose distribution into finite calculation elements. Coarse sampling can blur steep gradients and distort near-maximum doses or coverage estimates for small structures. Reducing grid spacing may improve representation but cannot repair inaccurate contours, beam models or transport algorithms. Evaluate whether clinically important metrics change with an appropriately refined grid. The relevant issue is resolution relative to anatomy and gradient scale, rather than a universal grid size.
Apply it
A tiny organ lies beside a steep stereotactic gradient, and its reported near-maximum dose changes substantially with grid refinement. Investigate calculation resolution and contour sampling before accepting the original metric as a stable representation of the organ's exposure.
Common pitfall: A fine display image does not prove that the underlying dose grid is fine. Interpolating a coarse result creates a smoother appearance without adding calculated physical detail.
AAPM TG-105: Clinical Implementation of Monte Carlo Treatment Planning · Radiation Oncology Physics: A Handbook for Teachers and Students
46.When is deformable dose accumulation credible?
Dose accumulation across changing anatomy requires a defensible correspondence between tissues, suitable registration and an understood dose-mapping method. Good image overlap alone does not validate transported dose. Tissue appearance or disappearance, sliding interfaces and major anatomical changes complicate correspondence and interpretation. Review the registration locally in clinically important regions and communicate uncertainty in the accumulated result. Biological conversion, when needed, adds separate assumptions and does not solve a faulty spatial mapping.
Apply it
Two treatment courses are mapped onto a common image, but registration distorts a critical organ boundary. Do not accept the summed maximum solely because the software produces a number. Review correspondence and consider alternative estimates or bounded interpretations for that region.
Common pitfall: Adding DVH maxima from separate courses does not establish a common tissue maximum. Deformable mapping also cannot be considered validated simply because contours overlap after transformation.
AAPM TG-132: Image Registration and Fusion in Radiotherapy · AAPM Report 166: The Use and QA of Biologically Related Models for Treatment Planning
Brachytherapy5%
47.How does source decay change HDR dwell time?
For unchanged geometry and dose-rate proportionality, dose from an HDR dwell is proportional to source strength multiplied by dwell time. As source strength decreases through radioactive decay, longer dwell times are required to reproduce the same dose distribution. Use the calibrated source strength at its reference date and the correct treatment date. This relationship assumes that source model, dwell positions and relative dwell weighting remain unchanged; it does not replace source-strength verification.
Apply it
A hypothetical HDR source has half its earlier strength. With identical applicator geometry and relative dwell weighting, doubling all dwell times reproduces the earlier calculated dose. Confirm that the treatment system uses the correct dated strength before approving the updated timing.
Common pitfall: Increasing source age does not reduce the prescribed dose when timing is correctly adjusted. Using activity interchangeably with the system's calibrated strength quantity can introduce errors.
AAPM Medical Physics Practice Guideline 13.a: HDR Brachytherapy, Part A · Radiation Oncology Physics: A Handbook for Teachers and Students
48.Why are applicator reconstruction and dwell geometry critical?
Brachytherapy dose changes rapidly near a source, making source position and applicator reconstruction central to accuracy. A dwell coordinate must correspond to the physical source path and its defined reference, not merely the visible applicator outline. Source anisotropy and applicator geometry further shape dose. Check channel identity, reconstruction, offsets and active dwell locations before optimizing times. A favorable DVH can be misleading when calculated from an incorrectly reconstructed source path.
Apply it
A reconstructed channel is displaced relative to the visible applicator, yet optimization achieves the requested target coverage. Correct the reconstruction and source-path reference first, then recalculate and reoptimize. Dwell-time adjustments cannot reliably compensate for an incorrectly modeled source location.
Common pitfall: Near-source dose is highly position-sensitive, but a point-source inverse-square estimate omits source geometry and anisotropy. Use it for intuition rather than as a complete clinical model.
AAPM Medical Physics Practice Guideline 13.a: HDR Brachytherapy, Part A · Radiation Oncology Physics: A Handbook for Teachers and Students
49.What survey is required before releasing a remote-afterloader patient?
Under U.S. NRC 10 CFR 35.604, the licensee must survey both the patient and the remote afterloader with a portable radiation detection survey instrument before releasing the patient from licensee control. The survey confirms that the source has been removed from the patient and returned to its safe shielded position. A console retraction indication or fixed room monitor does not replace this specified survey. Section 35.604 also requires survey records under [10 CFR 35.2404](https://www.ecfr.gov/current/title-10/chapter-I/part-35/subpart-L/section-35.2404): retain them for three years, including survey date, results, instrument used and the surveyor's name.
Apply it
After HDR delivery, perform the portable-instrument checks of the patient and afterloader before release and document the required information. If radiation near the applicator is unexpectedly elevated, maintain control of the patient and area and activate the established source-emergency procedure until source location is resolved.
Common pitfall: Successful console completion is not evidence that the legally specified survey occurred. A fixed room monitor provides additional information but does not fulfill the portable-instrument requirement. Permanent implants require a different source-retention and release assessment.
Federal Register :: Request Access · AAPM Medical Physics Practice Guideline 13.a: HDR Brachytherapy, Part A
Radiation Protection9%
50.How do time, distance and shielding reduce exposure?
ALARA uses practical measures to reduce unnecessary radiation exposure. Less time in a radiation field reduces accumulated dose; greater distance reduces exposure according to the applicable source geometry; shielding attenuates radiation according to its material, thickness and radiation type. These controls should support the required clinical task rather than compromise it. Distinguish reducing dose rate from reducing occupancy time, and check whether the source can be safely secured before relying on personal behavior.
Apply it
A training task requires work near a stationary pointlike source. Prepare tools before approaching, increase working distance where feasible and use suitable shielding. If dose rate remains constant, completing the same task in half the time halves the accumulated dose.
Common pitfall: Distance benefits depend on geometry; the inverse-square approximation is not universal near extended sources. Shielding must also suit the radiation rather than simply being thick.
51.What distinguishes primary and secondary shielding barriers?
A primary barrier is designed for the useful treatment beam striking it. A secondary barrier addresses leakage and radiation scattered from the patient or other structures, subject to the facility's beam geometry. Barrier classification follows the radiation that can reach the location, not its appearance or distance from the machine. Changes in beam direction, modality or equipment can alter shielding requirements. Evaluate the actual radiation components and adjacent occupied areas when interpreting a vault design.
Apply it
A proposed machine can direct its useful beam toward a wall that previously received only scatter and leakage. Reassess that wall as a potential primary barrier and review the surrounding shielding design before using the new beam directions clinically.
Common pitfall: A wall is not permanently secondary because it served that role for an older machine. Thickness alone cannot establish suitability without energy, geometry and workload assumptions.
IAEA Safety Reports Series 47: Radiation Protection in the Design of Radiotherapy Facilities
52.How do workload, use and occupancy affect shielding?
Workload represents the amount of radiation-producing clinical activity under the shielding design convention. The use factor describes the fraction directed toward a particular primary barrier, while occupancy represents how much the protected location is occupied. Together with distance, radiation quality and design goals, these factors determine required attenuation. Distinguish patient dose workload from machine output or MU-related leakage workload where appropriate. A change in practice can invalidate assumptions even when the physical vault remains unchanged.
Apply it
A department expands highly modulated treatments, increasing machine output for a similar prescribed patient dose. Review whether leakage-related workload assumptions still represent practice. Separately assess any change in how often nearby rooms are occupied or beams point toward particular barriers.
Common pitfall: Patient count alone may miss increased output from modulation. A low occupancy factor also needs a defensible description of real use rather than convenient assignment.
IAEA Safety Reports Series 47: Radiation Protection in the Design of Radiotherapy Facilities
53.How do U.S. NRC occupational limits, pregnancy provisions and monitoring triggers differ?
As of October 30, 2026, U.S. NRC 10 CFR 20.1201 limits adult annual occupational TEDE to 50 mSv. The accompanying annual limit for deep-dose equivalent plus committed dose equivalent to any individual organ or tissue other than the lens is 500 mSv; the lens-dose-equivalent limit is 150 mSv, and shallow-dose-equivalent limits for skin and extremities are 500 mSv. These limits apply together; planned special exposures have separate provisions. Section 20.1208 limits occupational embryo/fetus dose equivalent to 5 mSv over the entire declared pregnancy, including external and internal contributions, with efforts to avoid substantial variation above a uniform monthly exposure rate. Declaration is voluntary and written, includes estimated conception date, and may be withdrawn in writing under [20.1003](https://www.ecfr.gov/current/title-10/chapter-I/part-20/subpart-A/section-20.1003). If fetal dose already exceeds 5 mSv or is within 0.5 mSv of it at declaration, the remaining-pregnancy allowance is 0.5 mSv. Under 20.1502, adults likely to exceed 10% of an applicable annual limit from external sources require individual monitoring; declared pregnant workers require external monitoring if likely pregnancy deep-dose equivalent exceeds 1 mSv. These are monitoring triggers, not dose allowances.
Apply it
An adult likely to receive 6 mSv external deep-dose equivalent in a year crosses the 5 mSv monitoring trigger while remaining below the 50 mSv annual TEDE limit if no other contributions apply. A declared pregnant worker likely to receive 1.2 mSv external deep-dose equivalent during pregnancy crosses the separate 1 mSv monitoring trigger. Internal-intake monitoring has additional criteria under 20.1502, and entry into high or very high radiation areas also requires individual external monitoring.
Common pitfall: The 5 mSv fetal limit is for the whole pregnancy, not each month; the 1 mSv pregnancy trigger concerns external deep-dose equivalent rather than total fetal dose. NRC provisions govern their jurisdiction; Agreement State rules, state radiation-machine requirements and license conditions must also be identified. ALARA investigation levels prompt review and improvement and are distinct from legal limits or mandatory monitoring thresholds.
Federal Register :: Request Access · Federal Register :: Request Access · Federal Register :: Request Access · CDC: ALARA Recommendations
54.Which detector is suitable for a radiation survey?
Detector selection depends on radiation type, energy, expected dose rate, required sensitivity and temporal behavior. Ionization chambers, proportional counters and Geiger–Müller instruments have different response characteristics and limitations. A device appropriate for detecting low-level radiation may not accurately measure a high or pulsed field. Confirm calibration, operating range, background and functional checks before interpreting a reading. The measurement must answer the survey question, whether dose rate, contamination or source presence.
Apply it
A survey meter gives an unexpectedly low reading in a pulsed treatment environment. Check its suitability for pulsed fields, energy response and operating range, then use an appropriate measurement method. Do not infer adequate shielding from an instrument outside its validated application.
Common pitfall: A visible count rate is not automatically an accurate dose rate. Saturation, energy dependence or unsuitable pulse response can produce misleading readings despite apparent instrument operation.
Radiation Oncology Physics: A Handbook for Teachers and Students · IAEA Safety Reports Series 47: Radiation Protection in the Design of Radiotherapy Facilities
Quality Assurance & Standard of Care9%
55.How do commissioning and routine QA serve different purposes?
Commissioning establishes whether a system and its models perform accurately for intended clinical uses, creating a documented basis for patient work. Routine QA checks whether relevant performance remains consistent with accepted behavior. Constancy is valuable only when the baseline was valid. New techniques, software changes or hardware modifications may require additional validation beyond routine checks. Design tests around clinically meaningful failure modes rather than assuming that one standard measurement establishes every capability.
Apply it
A machine passes its usual output check after a software upgrade affecting delivery. Review the change and perform appropriate validation of the affected functions before clinical use. Stable reference output does not demonstrate that the altered delivery process is correct.
Common pitfall: Repeated agreement with an incorrect baseline preserves error. Routine output constancy also cannot substitute for commissioning a new energy, algorithm or complex delivery technique.
AAPM TG-275: Effective Physics Plan and Chart Review · AAPM TG-105: Clinical Implementation of Monte Carlo Treatment Planning
56.What makes a pretreatment plan and chart review effective?
An effective review tests consistency among the prescription, patient identity, images, contours, calculated dose and intended delivery. Timing matters: errors should be detected before the affected treatment whenever feasible. Review both numerical parameters and clinical relationships, such as whether dose is assigned to the intended target and fractionation. Automated checks can identify defined discrepancies, but their coverage is limited. Human review remains necessary for meaning, unusual cases and conflicting information.
Apply it
The plan's total dose matches the prescription, but its fraction count differs. Resolve the discrepancy before treatment because the dose per fraction and biological interpretation change. A matching total-dose field alone does not establish a correctly implemented prescription.
Common pitfall: A complete checklist can coexist with a missed clinical inconsistency. Reviewing only the final dose summary leaves image identity, plan version and delivery parameters insufficiently examined.
57.Why should an independent dose check use independent reasoning?
An independent calculation can reveal errors in normalization, geometry, modifiers or data transfer when it uses a sufficiently distinct method and verifies the relevant inputs. Agreement is less informative if both systems share the same wrong assumption. Understand the secondary method's limitations in heterogeneity, small fields and modulation before judging discrepancies. Investigate the cause rather than adjusting a factor merely to force agreement, and relate the check to the full plan-review process.
Apply it
A secondary calculation agrees after importing the same incorrect wedge selection as the TPS. Recognize that shared input errors can survive numerical agreement. Compare the intended physical setup and prescription independently, then repeat calculations with the verified modifier configuration.
Common pitfall: Independent software is not fully independent when it copies every unchecked input. Conversely, disagreement may reflect known method limitations rather than an error in the primary calculation.
AAPM TG-71: Monitor Unit Calculations for External Photon and Electron Beams · AAPM TG-275: Effective Physics Plan and Chart Review
58.How should a gamma passing rate be interpreted?
Gamma analysis combines dose-difference and distance-to-agreement criteria to compare distributions. Its result depends on normalization, threshold, spatial sampling, detector behavior and analysis settings. A high passing rate does not by itself prove correct target dose, organ dose or prescription implementation. Review the measurement setup, absolute dose information and spatial pattern of disagreement. Use the result as one component of verification, with clinically relevant investigation when discrepancies or independent checks raise concerns.
Apply it
A measured IMRT field passes the department's stated gamma criterion, but an independent absolute-dose check shows a systematic discrepancy. Investigate calibration, normalization and delivery rather than dismissing the dose result. The two tests may emphasize different aspects of agreement.
Common pitfall: Changing criteria until a plan passes changes the question being tested. A single aggregate percentage can also conceal a localized discrepancy near a clinically important gradient.
59.What can a record-and-verify system actually verify?
A record-and-verify system compares treatment settings with stored authorized parameters and records delivery information. It helps prevent certain setup and transfer errors, but it cannot independently establish that the stored plan is clinically correct. An incorrect approved parameter can be reproduced consistently. Verify patient identity, plan version, prescription relationship and transferred settings through the broader review process. Overrides and exceptional workflows require clear authorization and documentation because they weaken routine protective checks.
Apply it
The system correctly blocks treatment because the loaded accessory differs from the approved plan. Investigate which configuration is intended and correct the source of the mismatch. Do not bypass the interlock merely because the displayed patient and treatment field appear familiar.
Common pitfall: Successful verification means agreement with stored data, not proof of correct clinical intent. Repeated treatment of the wrong approved version remains a possible failure.
60.How should a near miss lead to safer practice?
A near miss reveals a failure pathway even when no incorrect treatment reaches the patient. Address the immediate discrepancy, preserve relevant facts and report through the established safety process. Analysis should examine workflow, interfaces, assumptions and protective barriers rather than stopping at individual blame. Corrective actions should target the demonstrated cause and be checked for effectiveness. Dosimetrists contribute within their professional role and escalate prescription or clinical decisions to the responsible team members.
Apply it
A final review catches a wrong plan version before delivery. Correct the patient record, document the near miss and examine why the obsolete version remained selectable. Introduce a targeted version-control improvement and later verify that it prevents the same pathway.
Common pitfall: Retraining alone may leave a defective interface or workflow unchanged. A near miss is also not evidence that every existing barrier works reliably under future conditions.
AAPM TG-275: Effective Physics Plan and Chart Review · MDCB Applicant Handbook 2027
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give Treatment Planning the largest share of study time: connect disease extent and nodal spread with anatomical boundaries, target selection, protocol-specific dose criteria, radiobiology and treatment technique.
- Practise decay, attenuation, inverse-square, dose-per-MU, BED and EQD2 calculations with explicit units and reference conditions.
- Review registrations and contours in three planes, distinguishing global overlap from clinically important local correspondence and identifying named anatomical landmarks.
- Explain why heterogeneity, small fields, dose grids and Monte Carlo sampling create different sources of calculation uncertainty.
- Distinguish cardiac-device risk categories, mandatory afterloader surveys, occupational dose limits, pregnancy provisions and personnel-monitoring triggers.
- Trace safety checks from prescription through approved plan transfer, independent verification, delivery and incident learning.
- Use the official matrix to identify topics beyond these 60 selected concepts, including additional disease sites, protocols, regulations and specialized procedures.
A practical preparation plan
1. Map knowledge to the official matrix
Create a row for each official task statement and mark whether you can explain it, calculate it or interpret a relevant image. Use the handbook as the complete scope and identify topics this selective guide does not cover.
2. Build a calculation notebook
Work decay, attenuation, geometric, MU and radiobiology examples without looking at solutions. For each result, record units, reference geometry, assumptions and a directional check explaining whether the answer should increase or decrease.
3. Practise spatial plan evaluation
On appropriate educational datasets, alternate between contours, isodoses and DVHs. Explain where underdose and hotspots occur, verify registration locally and compare organ metrics using the correct structure and fractionation definitions.
4. Challenge nominally acceptable plans
Ask what happens if anatomy changes, a registration is locally wrong, a beam crosses low-density tissue or a delivery parameter is transferred incorrectly. Link each failure to a suitable calculation, measurement or review.
5. Use drills to diagnose reasoning gaps
Complete the 20 questions, then explain why every alternative is less appropriate. Rework missed calculations with new numbers and use flashcards for spaced recall. Track concepts mastered rather than treating the score as a pass prediction.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- MDCB Applicant Handbook
- MDCB Applicant Handbook 2027
- MDCB Announce Dates for the 2027 Exam
- MDCB News
- Why Hire a CMD?
- MDCB Exam Development
- Radiation Oncology Physics: A Handbook for Teachers and Students
- IAEA-TECDOC-1560: Dose Reporting in Ion Beam Therapy
- AAPM Report 166: The Use and QA of Biologically Related Models for Treatment Planning
- AAPM TG-132: Image Registration and Fusion in Radiotherapy
- AAPM TG-71: Monitor Unit Calculations for External Photon and Electron Beams
- AAPM Report 85: Tissue Inhomogeneity Corrections for Megavoltage Photon Beams
- AAPM TG-105: Clinical Implementation of Monte Carlo Treatment Planning
- AAPM TG-275: Effective Physics Plan and Chart Review
- AAPM TG-218: IMRT Measurement-Based Verification QA
- AAPM TG-203: Management of Radiotherapy Patients with Implanted Cardiac Devices
- AAPM TG-290: Respiratory Motion Management for Particle Therapy
- AAPM Medical Physics Practice Guideline 13.a: HDR Brachytherapy, Part A
- IAEA Safety Reports Series 47: Radiation Protection in the Design of Radiotherapy Facilities
- CDC: ALARA Recommendations
- NCI: External Beam Radiation Therapy for Cancer
- TRACO: Introduction to Radiation Oncology, October 15, 2024
- NIST: Water Calorimetry Primary Standards for Absorbed Dose to Water
- Federal Register :: Request Access
- Federal Register :: Request Access
- Federal Register :: Request Access
- Federal Register :: Request Access
- radiation-therapy-and-you.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.